Compare JPMorgan Ultra Short Income ETF (JPST) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Ultra Short Income ETF vs Zoetis Inc — how do they compare? JPMorgan Ultra Short Income ETF trades at $50.3 (market cap $42.37B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: JPMorgan Ultra Short Income ETF is the larger of the two by market cap, and Zoetis Inc pays a 2.9% dividend while JPMorgan Ultra Short Income ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Ultra Short Income ETF for 47 Days and Zoetis Inc for 70 Days on average.
| JPST | ZTS | |
|---|---|---|
Market Cap | $42.37B | $30.20B |
Volume | 7,889,185 | 6,175,327 |
Sector | Fixed Income | Health |
52-Week High | $50.78 | $147.53 |
52-Week Low | $50.22 | $69.09 |
Typical Hold Time | 47 Days | 70 Days |
Enterprise Value | — | $37.76B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPMorgan Ultra-Short Income ETF (JPST) trades at $50.30 with minimal daily movement, showing stability typical of ultra-short bond funds. Technical indicators signal bearish momentum with moving averages in sell territory, though oversold RSI levels suggest potential near-term stabilization. Recent news highlights institutional position adjustments and growing investor interest in cash-alternative ETFs amid rising rate expectations.
The ETF faces headwinds from active management costs and competitive pressure from similar funds, though demand for ultrashort duration assets provides support. Key risks include interest rate sensitivity and fund flow volatility, while institutional ownership changes indicate mixed sentiment among professional investors.
Zoetis (ZTS) trades at $73.08, up 2.14% today, with a bullish technical signal but mixed earnings history including a recent Q1 2026 miss. The stock shows strong profitability with a 27.69% net income margin and 64.91% ROE, while valuation metrics like a P/E of 11.92 appear reasonable. Recent news highlights competitive pressures in the U.S. pet care market, though international segments remain resilient.
The outlook is cautiously optimistic; ZTS faces near-term headwinds from weak U.S. demand and competition, but its industry-leading margins and dominant market position support long-term growth. Risks include pricing erosion and guidance cuts, yet the consensus price target of $87.33 suggests upside potential for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Ultra Short Income ETF
JPST is an actively managed ETF that invests in short-term, investment-grade fixed income securities. It aims to provide current income and capital preservation while maintaining high liquidity.
Read more on JPST →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
